It has been clearly reported that FOSL1 can also promote the progression of pancreatic cancer (Vallejo et al., 2017; Luo, He & Qiu, 2018), bile duct cancer (Vallejo et al., 2021), breast cancer (Kim et al., 2020; Chen et al., 2018), bladder cancer (Cui et al., 2020; Gatta et al., 2019), stomach cancer (He et al., 2015) and esophageal cancer (Shen et al., 2020) through direct or indirect mechanisms. This evidence concerns the gene FOSL1 and urinary bladder cancer.